Market Cap

Inhibikase Therapeutics, Inc. Market Capitalization:

$8.3 Million

USD as of Jan. 1, 2024

business Inhibikase Therapeutics, Inc. Company Profile

Inhibikase Therapeutics, Inc. Main Stock Listing

NASDAQ: IKT

Market Capitalization History of Inhibikase Therapeutics, Inc.

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Top Competitors by Market Capitalization

Industry: Biotechnology
Company Market Cap (USD)
Novo Nordisk $461.52 B
Vertex Pharmaceuticals Incorporated $107.23 B
Regeneron Pharmaceuticals, Inc. $100.01 B
CSL Limited $94.74 B
Marinomed Biotech AG $73.23 B
Sector: Healthcare
Company Market Cap (USD)
Lilly $586.39 B
UnitedHealth Group $504.47 B
Novo Nordisk $461.52 B
Johnson & Johnson $387.50 B
Merck $296.51 B

Yearly evolution of Inhibikase Therapeutics, Inc. market cap

Date Market Cap YoY Change
Jan. 1, 2024 $8.3 M -50.51%
Jan. 1, 2023 $16.7 M -51.43%
Jan. 1, 2022 $34.4 M -78.98%
Jan. 1, 2021 $163.7 M

Market capitalization is calculated from the opening stock price at the beginning of each year.

Top 1-year algo backtest: +298.72%

$10,000 in April 2023 would now be $39,872 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Inhibikase Therapeutics, Inc. Categories

United States languages Healthcare languages Biotechnology
United States Healthcare United States Biotechnology

Stocks & Indices

Inhibikase Therapeutics, Inc. has the following listings and related stock indices.


Stock: NASDAQ: IKT

What is a company's market capitalization?

The market capitalization of a company, more simply referred to as "market cap", is the total market value of a publicly traded company's outstanding shares. It is often considered as a key indicator of what a company is worth.